Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Eiffage, a major European construction and concession company, recently reported its half-year results.</li><li>Several key highlights emerge from their presentation.</li><li>Firstly, Eiffage underscored robust growth in both its construction and concession activities.</li></ul>

Eiffage, a major European construction and concession company, recently reported its half-year results.Several key highlights emerge from their presentation.Firstly, Eiffage underscored robust growth in both its construction and concession activities.

Eiffage SA Doubles Down on Growth — But Can Its Massive CapEx Bets Pay Off?

<ul><li>Eiffage, a French multinational involved in construction and concessions, presented its 2024 annual results highlighting a robust year in terms of both performance and strategic acquisitions.</li><li>The company reported strong earnings and record order intake, reflecting a solid operational year bolstered by major new contracts and consistent cash flow generation.</li><li>On the positive side, Eiffage's order book reached a record level by the end of 2024, growing by 11% compared to the previous year.</li></ul>

Eiffage, a French multinational involved in construction and concessions, presented its 2024 annual results highlighting a robust year in terms of both performance and strategic acquisitions.The company reported strong earnings and record order intake, reflecting a solid operational year bolstered by major new contracts and consistent cash flow generation.On the positive side, Eiffage's order book reached a record level by the end of 2024, growing by 11% compared to the previous year.

Eiffage: Initiation of Coverage- From Lagging Returns To A Potential Growth Engine—Can Strategic Deals Turn the Tide?

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

iShares MSCI ACWI ETF / Technical Analysis

<ul>
<li>The pullback in global equities continues with the MSCI ACWI (ACWI-US) testing 1.5-month downtrend resistance while the STOXX Europe 50 tests resistance at 3800-3840.</li>
<li>We expect a rejection at the 1.5-month downtrend and for the stair-step lower to continue, with our targets being $84 (December 2022 low) and potentially $75-77 (the 2022 lows).</li>
<li>If ACWI-US is able to reverse above the 1.5-month downtrend, we still expect $93 to cap upside in 2023. Remain overweight Europe. Also highlighting individual stock buys on pullbacks.</li>
</ul>


The pullback in global equities continues with the MSCI ACWI (ACWI-US) testing 1.5-month downtrend resistance while the STOXX Europe 50 tests resistance at 3800-3840.
We expect a rejection at the 1.5-month downtrend and for the stair-step lower to continue, with our targets being $84 (December 2022 low) and potentially $75-77 (the 2022 lows).
If ACWI-US is able to reverse above the 1.5-month downtrend, we still expect $93 to cap upside in 2023. Remain overweight Europe. Also highlighting individual stock buys on pullbacks.


MSCI ACWI and EAFE Testing 1.5-Month Downtrends; Remain OW EU; Buys in Leading Sectors on Pullbacks

EURO STOXX 50 Price EUR / Technical Analysis

<ul>
<li>It appears the recent pullback is over, and we could see the MSCI ACWI (ACWI-US) test YTD highs at $93. We still expect $93 to cap upside in 2023.</li>
<li>Overweight Europe/UK and non-U.S., we are buyers on pullbacks as long as FTSE 100 is above 7700, STOXX Europe 50 is above 3800, and EURO STOXX 50 is above 4000.</li>
<li>As long as these support levels are holding, we are constructive from a price perspective</li>
</ul>


It appears the recent pullback is over, and we could see the MSCI ACWI (ACWI-US) test YTD highs at $93. We still expect $93 to cap upside in 2023.
Overweight Europe/UK and non-U.S., we are buyers on pullbacks as long as FTSE 100 is above 7700, STOXX Europe 50 is above 3800, and EURO STOXX 50 is above 4000.
As long as these support levels are holding, we are constructive from a price perspective


Remain Overweight Europe/UK & Non-US Equities; Pullback Over?; Buys in Industrials and Financials

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>IFM Investors is seeking to amass a 15% interest in <a href="https://www.smartkarma.com/entities/atlas-arteria-ltd" target="_blank" data-smartkarma-citation="entities:14430:1" rel="noopener">Atlas Arteria (ALX AU)</a> through a combination of total return swaps and physical shares, <a href="https://www.afr.com/street-talk/atlas-arteria-in-departures-lounge-as-ifm-investors-makes-big-move-20220607-p5arso" target="_blank" rel="noopener">according to AFR</a>.</li>
<li>If successful in securing its stake, IFM intends to request due diligence access to judge if it can lob a privatisation proposal. </li>
<li>Jarden, IFM’s broker, was buying shares at A$8.10 a share, a 14% premium to the last close but below the Australian takeover premium range of 20% to 40%.</li>
</ul>


IFM Investors is seeking to amass a 15% interest in Atlas Arteria (ALX AU) through a combination of total return swaps and physical shares, according to AFR.
If successful in securing its stake, IFM intends to request due diligence access to judge if it can lob a privatisation proposal. 
Jarden, IFM’s broker, was buying shares at A$8.10 a share, a 14% premium to the last close but below the Australian takeover premium range of 20% to 40%.


Atlas Arteria in the Crosshairs of IFM Investors

France

Eiffage SA is a contractor and a concessionaire. The Company operates through numerous business lines, including concessions and public-private partnerships, construction, public works, energy, metal. Eiffage offers its products and services throughout Europe and Senegal.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Eiffage SA (FGR FP)

Eiffage SA Doubles Down on Growth — But Can Its Massive CapEx Bets Pay Off?

Eiffage, a major European construction and concession company, recently reported its half-year results. Several key highlights emerge from their...

Baptista Research

Eiffage: Initiation of Coverage- From Lagging Returns To A Potential Growth Engine—Can Strategic Deals Turn the Tide?

Eiffage, a French multinational involved in construction and concessions, presented its 2024 annual results highlighting a robust year in terms of...

Baptista Research

MSCI ACWI and EAFE Testing 1.5-Month Downtrends; Remain OW EU; Buys in Leading Sectors on Pullbacks

Pullback in global equities continues with MSCI $ACWI testing 1.5-month downtrend resistance as $STOXX Europe 50 tests 3800-3840 resistance....

Vermilion Research

Remain Overweight Europe/UK & Non-US Equities; Pullback Over?; Buys in Industrials and Financials

Remain overweight Europe/UK and non-US equities; we are buyers on pullbacks as long as the FTSE 100 is above 7700, the STOXX Europe 50 is above...

Vermilion Research

Atlas Arteria in the Crosshairs of IFM Investors

IFM Investors is seeking to amass a 15% interest in Atlas which could lead to a privatisation proposal. IFM's buying at A$8.10 sets a floor price...

Arun George

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)